Russell Investments Group
FULC icon

Russell Investments Group’s Fulcrum Therapeutics FULC Stock Holding History

Russell Investments Group’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$381K Buy
104,199
+25,042
+32% +$152K ﹤0.01% 2905
2026
Q1 		$607K Buy
79,157
+75,583
+2,115% +$701K ﹤0.01% 2427
2025
Q4 		$40.4K Sell
3,574
-10,157
-74% -$103K ﹤0.01% 3378
2025
Q3 		$126K Buy
13,731
+4,423
+48% +$32K ﹤0.01% 2958
2025
Q2 		$64K Buy
9,308
+9,092
+4,209% +$48.6K ﹤0.01% 2923
2025
Q1 		$622 Sell
216
-98
-31% -$360 ﹤0.01% 3653
2024
Q4 		$1.48K Buy
314
+267
+568% +$985 ﹤0.01% 3488
2024
Q3 		$168 Buy
+47
New +$349 ﹤0.01% 3653
2023
Q2 		– Sell
-925
Closed -$2.64K – 3479
2023
Q1 		$2.64K Buy
+925
New +$8.29K ﹤0.01% 2988
2021
Q1 		– Sell
-1,300
Closed -$15K – 3132
2020
Q4 		$15K Hold
1,300
– – ﹤0.01% 2992
2020
Q3 		$10K Hold
1,300
– – ﹤0.01% 3151
2020
Q2 		$23K Buy
+1,300
New +$20.5K ﹤0.01% 3046

Other funds holding FULC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Russell Investments Group's FULC Position: Q2 2026 in Review

Russell Investments Group increased its Fulcrum Therapeutics (FULC) stake by 32% in Q2 2026, buying an estimated $152K and bringing the position to 104,199 shares worth $381K. The position accounts for ﹤0.01% of the portfolio, ranked #2905.

Russell Investments Group first reported a position in FULC in Q2 2020 and has held it in 12 quarters since. The position peaked at $607K in Q1 2026. 50 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

  • Russell Investments Group held 104,199 shares of Fulcrum Therapeutics worth $381K as of Q2 2026.
  • Russell Investments Group bought 25,042 Fulcrum Therapeutics shares in Q2 2026, an estimated $152K.
  • Fulcrum Therapeutics made up ﹤0.01% of Russell Investments Group's portfolio in Q2 2026, its #2905 holding.
  • Russell Investments Group first reported a position in Fulcrum Therapeutics in Q2 2020 and has held it in 12 quarters since.
  • Russell Investments Group's Fulcrum Therapeutics position peaked at $607K in Q1 2026.
  • 50 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.